1° CONVEGNO SIURO LOMBARDIA Il Carcinoma della prostata nel terzo millennio INTRODUZIONE G. Comeri Centro Convegni LE ROBI...
American Cancer Society , Cancer Facts & Figures 2005 Annual Percentage of Change 1975-87 +0.9% 1987-91  +3.0% 1994-01  -4...
American Cancer Society , Cancer Facts & Figures 2005 Relative Survival Rates Survival in relation to men who do  not  hav...
Relative Survival* (%) during Three Time Periods   <ul><li>Breast (female) 75 78 87 </li></ul><ul><li>Colon & rectum 50 57...
Changes in Relative 5-Year Survival Rates
Changes in WHO Age-Adjusted Prostate Cancer Mortality Rates V Gr Sp Sw Be  NoLu Ir  Fi D It Ne Fr A Ca UK G US The decreas...
PSA Screening Program and Its Effect on Tyrol’s Prostate Cancer Mortality Rate Horninger W, MD et al  Am J Urol Review  20...
Population-Based Case-Control Studies <ul><li>Bergstralh J et al, Population-Based Case-Control Study of PSA and DRE Scree...
Typical Pathology Diagrams of Prostates with Cancers in  2005 PSA Level:  2.5 2mm 3 PSA Level:  6.0 2mm 3 urethra urethra
Typical Pathology Diagrams of Prostates with Cancers in  1991 PSA Level:  2.5 2mm 3 15mm 3 PSA Level:  17.5 urethra urethra
T1c Patients with RRP by PSA at Diagnosis  (PSA Follow-up Study,2005) 2.6-4.0 4.1-6.0 6.1-9.9 >  10 Number of Months 120 1...
PSA Velocity <ul><li>More meaningful than the absolute PSA level </li></ul><ul><li>Increases over time </li></ul>
Use PSA Intelligently <ul><li>PSA provides a continuum of risk </li></ul><ul><li>Get away from PSA cutoffs </li></ul><ul><...
N Engl J Med. 2004 May 27;350(22):2239-46.
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. 7% 10% 17% 24%...
National Comprehensive Cancer Center Network (NCCN) Guidelines <ul><li>Begin screening at age 40 </li></ul><ul><li>If PSA ...
Simple, non-invasive urine specimen collected post-DRE Groskopf J, et al. Clin Chem 2006;52:1089-95
What is measured in the urine post-DRE ?
 
Upcoming SlideShare
Loading in...5
×

Il carcinoma della prostata nel terzo millennio

1,184

Published on

Il dott. Comeri presenta dati, prospettive e soluzioni per il trattamento del carcinoma alla prostata alla luce delle scoperte del nuovo millennio

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
1,184
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide
  • The survival rate for all cancers combined and for certain site-specific cancers have improved significantly since the 1970s, due, in part, to both earlier detection and advances in treatment. Survival rates markedly increased for cancers of the prostate, ovary, breast, colon &amp; rectum, and for leukemia. With new treatment techniques and increased utilization of screening, there is hope for even greater improvements in the not-too-distant future.
  • Transcript of "Il carcinoma della prostata nel terzo millennio"

    1. 1. 1° CONVEGNO SIURO LOMBARDIA Il Carcinoma della prostata nel terzo millennio INTRODUZIONE G. Comeri Centro Convegni LE ROBINIE Solbiate Olona (Va) 25 ottobre 2008
    2. 2. American Cancer Society , Cancer Facts & Figures 2005 Annual Percentage of Change 1975-87 +0.9% 1987-91 +3.0% 1994-01 -4.1%
    3. 3. American Cancer Society , Cancer Facts & Figures 2005 Relative Survival Rates Survival in relation to men who do not have prostate cancer 1995-2005 stage at diagnosis 90% localized 5% distant
    4. 4. Relative Survival* (%) during Three Time Periods <ul><li>Breast (female) 75 78 87 </li></ul><ul><li>Colon & rectum 50 57 62 </li></ul><ul><li>Leukemia 34 41 46 </li></ul><ul><li>Lung & bronchus 12 14 15 </li></ul><ul><li>Melanoma 80 85 90 </li></ul><ul><li>Non-Hodgkin lymphoma 47 54 56 </li></ul><ul><li>Ovary 37 41 53 </li></ul><ul><li>Pancreas 3 3 4 </li></ul><ul><li>Prostate 67 75 98 </li></ul><ul><li>Urinary bladder 73 78 82 </li></ul>* 5-year relative survival rates based on follow up of patients through 2000 . Source: Surveillance, Epidemiology, and End Results Program, 1975-2000, Division of Cancer Control and Population Sciences, National Cancer Institute, 2003 .     Site 1974-1976 1983-1985 1992-1999 2000 99% Relative to normal life expectancy
    5. 5. Changes in Relative 5-Year Survival Rates
    6. 6. Changes in WHO Age-Adjusted Prostate Cancer Mortality Rates V Gr Sp Sw Be NoLu Ir Fi D It Ne Fr A Ca UK G US The decrease in the UK in the absence of widespread PSA screening is caused by a change in software that attributes cause of death.
    7. 7. PSA Screening Program and Its Effect on Tyrol’s Prostate Cancer Mortality Rate Horninger W, MD et al Am J Urol Review 2005 Apr 3:4, 172-175 1993 Mass screening project launched in Tyrol, Austria, offers PSA testing free to all men ages 45-75; 65,123 enrolled Treatment for Tyrol subjects with: Elevated PSA levels  advised to undergo DRE and biopsies Organ-confined lesions  RRP or EBR T3 lesions  EBR only Metastases  ADT No organized screening in the rest of Austria. Treatments varied. WJC
    8. 8. Population-Based Case-Control Studies <ul><li>Bergstralh J et al, Population-Based Case-Control Study of PSA and DRE Screening on Prostate Cancer Mortality (Rochester, MN) AUA Abstract 535 </li></ul><ul><li>Less screening in patients who died of CaP </li></ul><ul><li>Kopec et al, Screening with PSA and Metastatic Prostate Cancer Risk: Population-Based Case Control Study (Toronto, Ontario) AUA Abstract 541 </li></ul><ul><li>Less screening in men who developed metastases </li></ul>
    9. 9. Typical Pathology Diagrams of Prostates with Cancers in 2005 PSA Level: 2.5 2mm 3 PSA Level: 6.0 2mm 3 urethra urethra
    10. 10. Typical Pathology Diagrams of Prostates with Cancers in 1991 PSA Level: 2.5 2mm 3 15mm 3 PSA Level: 17.5 urethra urethra
    11. 11. T1c Patients with RRP by PSA at Diagnosis (PSA Follow-up Study,2005) 2.6-4.0 4.1-6.0 6.1-9.9 > 10 Number of Months 120 100 80 60 40 20 0 Probability of No PSA Progression 1.0 .9 .8 .7 .6 .5 .4 .3 .2 .1 0.0 Tumor volume is not the most important outcome
    12. 12. PSA Velocity <ul><li>More meaningful than the absolute PSA level </li></ul><ul><li>Increases over time </li></ul>
    13. 13. Use PSA Intelligently <ul><li>PSA provides a continuum of risk </li></ul><ul><li>Get away from PSA cutoffs </li></ul><ul><li>Rule out prostatitis and repeat PSA measurements </li></ul><ul><li>Use PSA density, PSA Velocity, and free and complexed PSA </li></ul>
    14. 14. N Engl J Med. 2004 May 27;350(22):2239-46.
    15. 15. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. 7% 10% 17% 24% 27% 1% 1% 2% 5% 7% 0 5 10 15 20 25 30 ? 0-0.5 0.6-1.0 1.1-2.0 2.1-3.0 3.1-4.0 PSA Level (ng/ml) % of Men with Prostate Cancer and High- Grade Disease Percent with Prostate Cancer Percent with Gleason > 7 Disease Thompson IM, et al. N Engl J Med. 2004 May 27;350(22):2239-46 . (13%) (10%) (12%) (19%) (25%) Relationship of the PSA Level to the Prevalence of Prostate Cancer and High-Grade Disease
    16. 16. National Comprehensive Cancer Center Network (NCCN) Guidelines <ul><li>Begin screening at age 40 </li></ul><ul><li>If PSA > 0.6 ng/ml - screen annually </li></ul><ul><li>If PSA Velocity > 0.4, consider biopsy </li></ul><ul><li>If PSA = 2.6-4 ng/ml, consider biopsy </li></ul>National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology – v.1.2004, Prostate Cancer Early Detection
    17. 17. Simple, non-invasive urine specimen collected post-DRE Groskopf J, et al. Clin Chem 2006;52:1089-95
    18. 18. What is measured in the urine post-DRE ?

    ×